With Bayer Deal Gone, Lion s Revenues Set To Continue Sliding; Cost Cutting Expected | GenomeWeb

Note: This article has been updated to clarify the details of Lion's relationship with Bayer and its plans for a Nasdaq delisting, and to correct the names of the company's products in the 10th paragraph.

Reporting its financial results for its fiscal first quarter last Thursday, Lion Bioscience said it expects revenues to continue their downhill slide in the next quarter due to the expiration of its five-year target discovery project with Bayer at its LBRI facility in Cambridge, Mass.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.